PMEF
NKTR icon

Point72 Middle East FZE’s Nektar Therapeutics NKTR Stock Holding History

Point72 Middle East FZE’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,143
Closed -$78.9K – 1729
2023
Q2 		$78.9K Buy
+9,143
New +$97.5K ﹤0.01% 1235
2023
Q1 		– Sell
-2,272
Closed -$77K – 2024
2022
Q4 		$77K Buy
+2,272
New +$110K ﹤0.01% 1354

Other funds holding NKTR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

Point72 Middle East FZE's NKTR Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Nektar Therapeutics (NKTR) in Q3 2023, closing a stake of 9,143 shares — an estimated $78.9K sold.

Point72 Middle East FZE first reported a position in NKTR in Q4 2022 and held it in 2 quarters. The position peaked at $78.9K in Q2 2023. 138 funds tracked by Wall St. Rank hold NKTR as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Nektar Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 9,143 Nektar Therapeutics shares in Q3 2023, an estimated $78.9K.
  • Point72 Middle East FZE first reported a position in Nektar Therapeutics in Q4 2022 and held it in 2 quarters.
  • Point72 Middle East FZE's Nektar Therapeutics position peaked at $78.9K in Q2 2023.
  • 138 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.